The Center for Interventional Medicine for Precision and Advanced Cellular Therapy, IMPACT, at Universidad de los Andes, announced the signing of a strategic alliance with INBISTRA to strengthen the translational development of its scientific portfolio.
INBISTRA is an international firm specialized in strategy and development in biotechnology, which supports the evaluation and projection of scientific programs toward clinical development stages. Through this collaboration, both institutions will work to strengthen the strategic framing of IMPACT’s pipeline, supporting processes of program positioning, prioritization, and definition of development pathways as initiatives evolve from early research stages toward more structured translational phases.
“In the consolidation stage in which IMPACT currently finds itself, INBISTRA’s experience has been key in helping us structure the development pathway of our programs and strengthen our ability to translate innovative solutions into real opportunities for patients,” said Miguel Rebolledo, general manager of the Basal Center IMPACT.
For Ignacio Sancho-Martínez, Managing Partner of INBISTRA: “This alliance is a natural extension of our mission, supporting early-stage and academically rooted biotechnology programs with the strategy and asset prioritization frameworks needed to ensure their translational pathway.”
The alliance also reflects the growing relevance of strengthening links between the European and Latin American biopharmaceutical ecosystems, an axis of collaboration with high potential to drive the global development of advanced therapies.